Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole clinical drug forward

At its peak, ALX Oncology $ALXO was trading at $88 per share, riding on the promise of blocking CD47, which cancer cells use to broadcast a “don’t eat me” signal. Today, it’s at under $13. The plunge came after two readouts late...

Click to view original post